Updated
Lexaria BioscienceLEXX · Healthcare
$4.50+7.91%
Market cap$112M
IndustryBiotechnology
Lexaria Bioscience (LEXX) Financial statements
Lexaria Bioscience reported revenue of $705,923 in fiscal 2025, up 37.3% a year over 9 years.
Key figures
Net income was -$12M and the operating margin -1683.0%, against -3136.8% in 2016. Free cash flow was -$10M. The diluted share count fell 59% over the period (buybacks).
- Revenue, FY2025
- $705,923+52.0% on 2024
- Net income
- -$12M+105.4% on 2024
- Operating margin
- -1683.0%
- Free cash flow
- -$10M+109.4% on 2024
Revenue and free cash flow
Fiscal years, from Lexaria Bioscience's 10-K filings.
Lexaria Bioscience revenue and free cash flow
FY2016–FY2025LEXXRevenue$1MLEXXFree cash flow-$10M
Margins
How much of each dollar of revenue is left after the cost of sales, after operating costs, and at the bottom line.
Lexaria Bioscience margins
FY2016–FY2025LEXXGross margin100%LEXXOperating margin-1683%LEXXNet margin-1686%
Financial statements
Fiscal 2016–2025.
Lexaria Bioscience income statement, fiscal 2016–2025
| USD | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $40,718 | $63,639 | $433,287 | $222,610 | $384,543 | $722,738 | $255,397 | $226,208 | $464,278 | $705,923 |
| Cost of revenue | $45,615 | $29,750 | $25,185 | $22,893 | $99,378 | $175,346 | $71,841 | $31,500 | $4,822 | $2,720 |
| Gross profit | -$4,897 | $33,889 | $408,102 | $199,717 | $215,415 | $547,392 | $183,556 | $194,708 | $459,456 | $703,203 |
| Research and development | $9,024 | $54,185 | $492,864 | $555,730 | $387,074 | $1M | $2M | $4M | $2M | $8M |
| Selling, general and admin | $133,679 | $129,726 | $217,655 | $297,209 | $4M | $5M | $5M | $3M | $4M | $4M |
| Operating income | -$1M | — | — | — | $257,623 | -$6M | -$7M | -$7M | -$6M | -$12M |
| Interest expense | $2,250 | $6,015 | — | — | — | — | — | $0 | $7,760 | — |
| Pre-tax income | -$1M | -$2M | -$7M | -$4M | -$4M | -$4M | -$7M | -$7M | -$6M | -$12M |
| Income tax | $0 | $0 | $0 | $17,664 | $2,319 | $6,093 | $0 | — | — | — |
| Net income | -$1M | -$2M | -$7M | -$4M | -$4M | -$4M | -$7M | -$7M | -$6M | -$12M |
| EPS (diluted) | -$0.03 | -$0.03 | -$0.09 | -$0.05 | -$1.47 | -$0.95 | — | -$1.01 | -$0.47 | -$0.66 |
| Diluted shares | 44M | 59M | 71M | 78M | 3M | 4M | — | 7M | 12M | 18M |
| Gross margin | -12.0% | 53.3% | 94.2% | 89.7% | 56.0% | 75.7% | 71.9% | 86.1% | 99.0% | 99.6% |
| Operating margin | -3136.8% | — | — | — | 67.0% | -786.8% | -2591.7% | -2888.5% | -1239.2% | -1683.0% |
| Net margin | -3136.8% | -3031.9% | -1525.4% | -1868.0% | -1062.2% | -579.2% | -2846.3% | -2946.4% | -1248.2% | -1686.0% |
Lexaria Bioscience balance sheet, fiscal 2016–2025
| USD | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $93,409 | $3M | $2M | $1M | $1M | $12M | $6M | $1M | $7M | $2M |
| Receivables | $131,083 | $45,293 | $265,751 | $273,145 | $313,925 | $342,401 | $201,784 | $126,686 | $154,477 | $368,358 |
| Inventory | $134,724 | $67,174 | $87,233 | $127,396 | $116,871 | $29,648 | $38,418 | $0 | — | — |
| Total current assets | $510,166 | $3M | $2M | $2M | $2M | $12M | $7M | $2M | $8M | $3M |
| Property, plant and equipment | $2,475 | $1,856 | $1,237 | $591,263 | $483,357 | $368,213 | $315,505 | $254,143 | $254,709 | $228,129 |
| Total assets | $566,638 | $3M | $2M | $3M | $3M | $13M | $8M | $3M | $9M | $4M |
| Total current liabilities | $433,881 | $92,347 | $43,640 | $184,507 | $225,917 | $153,276 | $194,036 | $267,735 | $1M | $1M |
| Long-term debt | $45,000 | $0 | $0 | $0 | — | — | — | $0 | $0 | $0 |
| Total liabilities | $478,881 | $92,347 | $43,640 | $184,507 | $345,980 | $203,265 | $201,437 | $403,908 | $1M | $2M |
| Shareholders' equity | $266,045 | $3M | $2M | $2M | $2M | $13M | $8M | $3M | $8M | $3M |
| Net debt | -$48,409 | -$3M | -$2M | -$1M | -$1M | -$11M | -$6M | -$1M | -$6M | -$2M |
Lexaria Bioscience cash flow, fiscal 2016–2025
| USD | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$660,856 | -$2M | -$3M | -$3M | -$3M | -$4M | -$5M | -$6M | -$5M | -$10M |
| Capital spending | $3,094 | $0 | — | $646,183 | $0 | — | $49,192 | $33,748 | $43,014 | $24,646 |
| Free cash flow | -$663,950 | -$2M | — | -$4M | -$3M | — | -$5M | -$6M | -$5M | -$10M |
| Stock-based compensation | $122,015 | $113,044 | $3M | $626,692 | $1M | $410,007 | $752,591 | $170,382 | $492,236 | $859,494 |
| Net borrowing | — | — | — | — | $30,670 | -$22,744 | $0 | — | — | — |
| Free cash flow margin | -1630.6% | -2429.2% | — | -1640.4% | -681.0% | — | -1929.8% | -2614.8% | -1077.4% | -1483.9% |
How Lexaria Bioscience compares
Lexaria Bioscience's operating margin is higher than 5% of Healthcare companies and 1% of the 2,820 companies with an operating margin figure.
| Higher than | Healthcare | All stocks |
|---|---|---|
| Operating margin | 5% | 1% |
| Net margin | 4% | 1% |
| Gross margin | 99% | 100% |
| Revenue growth | 7% | 2% |
| ROE | 4% | 2% |
Questions about Lexaria Bioscience
What was Lexaria Bioscience's revenue in 2025?
$705,923 in fiscal 2025, from its 10-K filing.
How much free cash flow does Lexaria Bioscience generate?
-$10M in fiscal 2025 (operating cash flow minus capital spending).
From Lexaria Bioscience's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.